v3.8.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenues:        
Chronic illness monitoring supplies revenues $ 1,037,179 $ 1,858,926 $ 4,311,955 $ 4,972,196
Chronic illness monitoring fee revenues 159,025 317,156 599,339 888,453
Total Chronic illness monitoring revenues 1,196,204 2,176,082 4,911,294 5,860,649
Cost of revenues:        
Chronic illness monitoring supplies cost of revenues 733,143 1,269,828 3,054,086 3,878,972
Chronic illness monitoring fee cost of revenues 114,954 112,486 319,184 358,436
Total Chronic illness monitoring cost of revenues 848,097 1,382,314 3,373,270 4,237,408
Gross profit 348,107 793,768 1,538,024 1,623,241
Operating expenses:        
Selling, general and administrative (including $1,461,457, $1,004,211, $2,101,037 and $3,257,614, respectively, of stock-based compensation) 3,225,054 2,169,603 6,382,027 6,944,098
Research and development 56,191 57,611 307,137 139,023
Total operating expenses 3,281,245 2,227,214 6,689,164 7,083,121
Loss from operations (2,933,138) (1,433,446) (5,151,140) (5,459,880)
Other income (expense):        
Interest expense, net (2,198,631) (813,517) (6,856,258) (1,935,486)
Loss on settlement (750,000)   (750,000)  
Gain on derivatives liability 64,145 5,603,411 230,163 2,796,542
Loss on extinguishment of debt   (15,393) (2,499,212) (3,058,809)
Gain on disposal of property and equipment       245
Gain on liability settlements   8,859   295,099
Loss on induced conversions of debt       (379,132)
Other income 2,614   2,614  
Total other income (expense) (2,881,872) 4,783,360 (9,872,693) (2,281,541)
Net income (loss) (5,815,010) 3,349,914 (15,023,833) (7,741,421)
Deemed dividends on redemption of preferred stock       (6,484,236)
Dividends on preferred stock (58,978) (45,781) (127,335) (699,250)
Net loss attributable to common stockholders $ (5,873,988) $ 3,304,133 $ (15,151,168) $ (14,924,907)
Net loss per common share - basic $ (24.77) $ 15.18 $ (64.81) $ (81.57)
Net loss per common share - diluted $ (24.77) $ (3.78) $ (64.81) $ (82.78)
Weighted average common shares outstanding - basic 237,100 217,595 233,767 182,979
Weighted average common shares outstanding - diluted 237,100 260,266 233,767 201,928